The company funds innovation in two primary ways: directly, by co-funding late-stage clinical trials and product launches in exchange for future royalties; and indirectly, through the acquisition of existing royalties from original innovators in the industry. Currently, Royalty Pharma boasts a robust portfolio that includes over 35 commercially successful products, highlighted by well-known therapies such as Vertex's Trikafta, Johnson & Johnson's Tremfya, GSK's Trelegy, and Roche's Evrysdi. Additionally, the company has stakes in 17 development-stage product candidates, underlining its commitment to advancing innovation and patient care in the biopharmaceutical landscape. For more detailed information, Royalty Pharma encourages interested parties to visit their website or contact their investor relations department. This upcoming presentation at the Bernstein Healthcare Forum highlights the ongoing engagement of Royalty Pharma with investors and stakeholders in the biopharmaceutical industry.